Benzinga | Mar 10, 2021 04:41PM EST

C4 Therapeutics To Present On Discovery, Preclinical Development Of CFT7455 MonoDAC Degrader At American Association For Cancer Research Apr. 10

C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that a late-breaking abstract featuring preclinical data for CFT7455 has been selected for presentation at the first session of the American Association for Cancer Research (AACR) 2021 Annual Meeting, being held virtually April 10-15, 2021. CFT7455, the Company's most advanced protein degrader, targets IKZF1/3 for the treatment of hematologic malignancies.

Abstract Presentation Details

* Abstract: 5446

* Title: CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models

* Session: Late-Breaking Mini-symposium 1

* Session Time: 1:30 p.m. ET on Saturday, April 10, 2021

* Presenter: David Proia, Ph.D., Senior Director, In Vivo Pharmacology at C4T